Metformin Genethics Europe

Metformin Hydrochloride, the active ingredient in Metformin Genethics Europe, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels and is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformin Genethics Europe as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU manufacturing standards and providing the product to hospitals, pharmacies, and clinics worldwide through reliable distribution channels. Each batch includes full traceability documentation and certification to ensure quality.

Metformin, a biguanide antidiabetic agent, is used to improve glycemic control in disorders of glucose metabolism.

- Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c levels. - Impaired glucose tolerance (prediabetes): helps delay progression to overt diabetes. - Metabolic syndrome: improves insulin sensitivity and may aid weight management.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: liver enzyme elevations. - Hypoglycemia: usually when combined with insulin or sulfonylureas. - Anemia: due to reduced red blood cell production.

Metformin should be used with careful clinical monitoring.

- Renal function assessment: avoid in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: use cautiously in liver disease. - Lactic acidosis risk: discontinue before surgeries or radiologic contrast studies. - Alcohol consumption: limit intake to reduce acidosis risk. - Elderly patients: start at lower doses and monitor tolerance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; withhold metformin before and after exposure. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: potentiates lactic acidosis. - Diuretics (e.g., thiazides): may impair renal function and elevate metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors/ARBs: combined effect on renal function. - NSAIDs: can reduce renal clearance of metformin. - Warfarin: may alter INR, requiring monitoring. - Digoxin: potential for increased serum levels.